(39) TREATMENT OF ENDOMETRIAL CANCER IN A REGIONAL RADIATION THERAPY CENTER

Analysis of 379 Consecutive Patients

*John B. McCabe, M.S. III Robert H. Sagerman, M.D.

Division of Radiation Oncology Department of Radiology

State University of New York Upstate Medical Center

Syracuse, New York

The Radiation Oncology Division of the Upstate Medical Center is the sole provider of radiation therapy services for a large geographic region centering about Syracuse, N.Y. 472 patients with endometrial cancer were seen in the years 1964 to 1974. 379 received irradiation as part of the initial ther- apy for adenocarcinoma and are analyzed here. All were re- staged according to the FIG0 classification, with 84% stage I, 10% stage II, and 6% in stages III & IV. 90% presented with abnormal vaginal bleeding. The average age was 60 years. There was a high incidence of hypertension, diabetes, and obesity. Overall survival was 74% at 5 years and 62.5% at 10 years. Survival was affected by age, stage, histologic differentiation and response to irradiation.

The recurrence rate was significantly lower (p .05) when the specimen was histologically negative (4%) then when posi- tive (13%) for stage I patients treated with a single intra- cavitary insertion (3500 rads to point A) followed 6-8 weeks later by total abdominal hysterectomy and bilateral salpingo- oophorectomy. Overall, 48 (12.7%) patients developed recur- rence following treatment; in only 5 (1.8%) was recurrence limited to the vagina. Recurrence was associated with advanced stage and poorly differentiated histology.

Reactions to irradiation, most commonly diarrhea, were encountered in 12% of all patients; these were proportionally more frequent with high dose whole pelvic irradiation.

A detailed analysis will be presented.

( 40) ANALYSIS OF TREATMENT RESULTS IN STAGE II ENDOMETRIAL CARCINOMA

H. Madoc-Jones, M. ., Ph.D.*l, F.R. Zivnuska, M.D.l, C.A. Perez, M.D.l, A. Galakatos, M.D. ! , and F. Askin, M.D.3

Departments of Radiation Oncologyl, GynecologyP, Surgical Pathology3, Washington University, School of Medicine, St. Louis, Missouri

Because Stage II (corpus et collum) comprises a rather small proportion of all endometrial carcinoma, prognostic factors for this stage are not as clearly established as those for Stage I.

49